MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on February 29, 2008; DOI: 10.1124/mol.107.044149


0026-895X/08/7306-1751-1760$20.00
Mol Pharmacol 73:1751-1760, 2008

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
mol.107.044149v1
73/6/1751    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kramer, M. A.
Right arrow Articles by Hines, R. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kramer, M. A.
Right arrow Articles by Hines, R. N.

Novel CYP2C9 Promoter Variants and Assessment of Their Impact on Gene ExpressionFormula

Melissa A. Kramer1, Allan E. Rettie, Mark J. Rieder, Erwin T. Cabacungan, and Ronald N. Hines

Departments of Pediatrics (M.A.K., E.T.C., R.N.H.) and Pharmacology and Toxicology (M.A.K., R.N.H.), Medical College of Wisconsin and Children's Research Institute (M.A.K., E.T.C., R.N.H.), Children's Hospital and Health System, Milwaukee, Wisconsin; and Departments of Medicinal Chemistry (A.E.R.) and Genome Sciences (M.J.R.), University of Washington, Seattle, Washington

There are a considerable number of reports identifying and characterizing genetic variants within the CYP2C9 coding region. Much less is known about polymorphic promoter sequences that also might contribute to interindividual differences in CYP2C9 expression. To address this problem, approximately 10,000 base pairs of CYP2C9 upstream information were resequenced using 24 DNA samples from the Coriell Polymorphism Discovery Resource. Thirty-one single-nucleotide polymorphisms (SNPs) were identified; nine SNPs were novel, whereas 22 were reported previously. Using both sequencing and multiplex single-base extension, individual SNP frequencies were determined in 193 DNA samples obtained from unrelated, self-reported Hispanic Americans of Mexican descent, and they were compared with similar data obtained from a non-Latino white cohort. Significant interethnic differences were observed in several SNP frequencies, some of which seemed unique to the Hispanic population. Analysis using PHASE 2.1 inferred nine common (>1%) variant haplotypes, two of which included the g.3608C>T (R144C) CYP2C9*2 and two the g.42614A>C (I359L) CYP2C9*3 SNPs. Haplotype variants were introduced into a CYP2C9/luciferase reporter plasmid using site-directed mutagenesis, and the impact of the variants on promoter activity assessed by transient expression in HepG2 cells. Both constitutive and pregnane X receptor-mediated inducible activities were measured. Haplotypes 1B, 3A, and 3B each exhibited a 65% decrease in constitutive promoter activity relative to the reference haplotype. Haplotypes 1D and 3B exhibited a 50% decrease and a 40% increase in induced promoter activity, respectively. These data suggest that genetic variation within CYP2C9 regulatory sequences is likely to contribute to differences in CYP2C9 phenotype both within and among different populations.


Received December 7, 2007; accepted February 28, 2008

Address correspondence to: Dr. Ronald N. Hines, Medical College of Wisconsin, TBRC/CRI/CPPT, 8701 Watertown Plank Rd., Milwaukee WI 53226. E-mail: rhines{at}mcw.edu







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics